Aptose Biosciences Net Worth
Aptose Biosciences Net Worth Breakdown | APTO |
Aptose Biosciences Net Worth Analysis
Aptose Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Aptose Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Aptose Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Aptose Biosciences' net worth analysis. One common approach is to calculate Aptose Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Aptose Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Aptose Biosciences' net worth. This approach calculates the present value of Aptose Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Aptose Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Aptose Biosciences' net worth. This involves comparing Aptose Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Aptose Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Aptose Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aptose Biosciences' net worth research are outlined below:
| Aptose Biosciences generated a negative expected return over the last 90 days | |
| Aptose Biosciences has some characteristics of a very speculative penny stock | |
| Aptose Biosciences has high historical volatility and very poor performance | |
| Aptose Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (51.21 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aptose Biosciences currently holds about 62.41 M in cash with (44.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: Antisense and RNAi Therapeutics Market Research Report 2023-2030 Expanding Use in Chronic and Inflammatory Diseases Drives Long-Term Market Opportunities - ResearchAndMarkets.com |
Aptose Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aptose Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aptose Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Aptose Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aptose Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aptose Biosciences backward and forwards among themselves. Aptose Biosciences' institutional investor refers to the entity that pools money to purchase Aptose Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Gleason Group, Inc. | 2024-09-30 | 1.2 K | Newbridge Financial Services Group, Inc. | 2024-06-30 | 832 | Advisor Group Holdings, Inc. | 2024-06-30 | 420 | Northwestern Mutual Wealth Management Co | 2024-06-30 | 133 | Group One Trading, Lp | 2024-06-30 | 115 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 102 | Pacific Capital Wealth Advisors, Inc | 2024-09-30 | 6.0 | Citigroup Inc | 2024-06-30 | 1.0 | Fidelity International Ltd | 2024-06-30 | 1.0 | Armistice Capital, Llc | 2024-06-30 | 1.7 M | Drw Securities, Llc | 2024-06-30 | 592.8 K |
Follow Aptose Biosciences' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.76 M.Market Cap |
|
Project Aptose Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.94) | (3.75) | |
| Return On Capital Employed | 22.96 | 24.11 | |
| Return On Assets | (3.94) | (3.75) | |
| Return On Equity | 17.65 | 18.53 |
When accessing Aptose Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Aptose Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aptose Biosciences' profitability and make more informed investment decisions.
Evaluate Aptose Biosciences' management efficiency
Aptose Biosciences has return on total asset (ROA) of (1.3629) % which means that it has lost $1.3629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9413) %, meaning that it created substantial loss on money invested by shareholders. Aptose Biosciences' management efficiency ratios could be used to measure how well Aptose Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Aptose Biosciences' Return On Capital Employed is very stable compared to the past year. As of the 22nd of November 2024, Return On Equity is likely to grow to 18.53, though Return On Tangible Assets are likely to grow to (3.75). At this time, Aptose Biosciences' Non Current Assets Total are very stable compared to the past year. As of the 22nd of November 2024, Other Current Assets is likely to grow to about 2.8 M, while Total Assets are likely to drop about 12.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.43) | (0.41) | |
| Tangible Asset Value | 23.6 M | 21 M | |
| Tangible Book Value Per Share | (0.43) | (0.41) | |
| Enterprise Value Over EBITDA | (0.17) | (0.16) | |
| Price Book Value Ratio | (5.91) | (5.62) | |
| Enterprise Value Multiple | (0.17) | (0.16) | |
| Price Fair Value | (5.91) | (5.62) | |
| Enterprise Value | -36.9 M | -35.1 M |
Understanding the operational decisions made by Aptose Biosciences management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Return On Equity (6.94) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aptose Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aptose Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aptose Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aptose Biosciences time-series forecasting models is one of many Aptose Biosciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aptose Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Aptose Biosciences Earnings per Share Projection vs Actual
Aptose Biosciences Corporate Management
| Brooks MBA | VP Controller | Profile | |
| Philippe Ledru | Senior Officer | Profile | |
| Janet CA | VP Fin | Profile | |
| Rafael MD | Senior Officer | Profile | |
| Roger BSc | Vice Operations | Profile | |
| Marc Wiles | Senior Affairs | Profile |
Already Invested in Aptose Biosciences?
The danger of trading Aptose Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aptose Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aptose Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aptose Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aptose Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptose Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptose Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptose Biosciences Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptose Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptose Biosciences. If investors know Aptose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptose Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.92) | Return On Assets (1.36) | Return On Equity (6.94) |
The market value of Aptose Biosciences is measured differently than its book value, which is the value of Aptose that is recorded on the company's balance sheet. Investors also form their own opinion of Aptose Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aptose Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptose Biosciences' market value can be influenced by many factors that don't directly affect Aptose Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptose Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptose Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptose Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.